Pharmacogenomic Research in Korean Patients With Hepatitis C

Inje University373 enrolled

Overview

The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV). And thus, the investigators are trying to develop the pharmacogenomic guideline in the Korean patients with HCV.

Study Type

OBSERVATIONAL

Enrollment

373

Conditions

Chronic Hepatitis C

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hepatitis C virus infected patients Exclusion Criteria: * Patients who infected Hepatitis B virus or Human immunodeficiency virus * HCV infected patients previously treated with antiviral drugs * Patients had a history of autoimmune hemolytic anemia

Locations (1)

Inje University

Busan, South Korea

Outcomes

Primary Outcomes

Sustained virological response (SVR)

Undetectable HCV RNA in serum ( \<15 IU/ml ) 24 weeks after the end of treatment

Time frame: 24 weeks after the end of treatment

Secondary Outcomes

Anemia

1. a reduction in Hemoglobin of \>3.0 g/dL 2. a reduction in Hemoglobin levels to 10.0g/dL.

Time frame: 4 weeks after start of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.